Orris

covid

Asking for Preferences
Reading File
Searching PubMed

"COVID-19"[MeSH Terms] AND "treatment"[MeSH Terms]

Searching the Web

COVID-19 symptoms treatment 2025 2026 current guidelines

Finding Sources
Searching PubMed

"COVID-19" AND ("nirmatrelvir" OR "antiviral" OR "treatment")

Reading Web Page

COVID-19 symptoms treatment 2026

Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Loading Image
Here is a thorough overview of COVID-19 symptoms and treatment, drawn from major medical textbooks and current guidelines.

COVID-19: Symptoms & Treatment

Transmission

SARS-CoV-2 spreads primarily via respiratory droplets and aerosols. Transmission peaks during the first 7-10 days of infection, especially in indoor, poorly ventilated spaces. The incubation period is 2-14 days, with a median of ~5 days. Asymptomatic people can still transmit the virus (accounting for ~20% of transmissions). - Goldman-Cecil Medicine, p. 3547

Symptoms

Most common:
  • Fever
  • Dry cough
  • Fatigue and myalgias
  • Anosmia (loss of smell) and ageusia (loss of taste) - hallmark features, though less common with Omicron/newer variants
  • Sore throat, headache, nasal congestion
  • Shortness of breath (more common in moderate/severe illness)
  • Nausea, vomiting, diarrhea (GI symptoms more prominent with Omicron-lineage variants)
2026 variants (e.g., NB.1.8.1): symptoms tend to be upper-respiratory dominant - congestion, runny nose, dry cough, fatigue, headache, body aches. Loss of taste/smell is less frequent than with earlier strains.

Severity Classification

Patients are classified into four groups:
SeverityDefinition
MildSymptoms present, no hypoxia (SpO2 >94%), no pneumonia
ModerateSpO2 ≥94%, lower respiratory tract disease on imaging
SevereSpO2 <94%, respiratory rate >30/min, lung infiltrates >50%
CriticalRespiratory failure, shock, or multiorgan dysfunction
Among unvaccinated adults: ~40% mild, ~40% moderate, ~15% severe, ~5% critical. - Goldman-Cecil Medicine, p. 3546
Risk factors for severe disease: Age >65, diabetes, obesity, cardiovascular disease, chronic lung disease, renal disease, immunosuppression, pregnancy, and being unvaccinated.

Treatment by Severity

COVID-19 treatment by severity - Goldman-Cecil Medicine

Mild illness (outpatient, low risk)

  • Supportive care: rest, hydration, acetaminophen/ibuprofen for fever and aches
  • No COVID-specific antivirals needed for low-risk individuals
  • Isolation to prevent transmission

Mild-to-moderate illness (outpatient, high risk of progression)

Antivirals should be started within 5 days of symptom onset. Priority order:
  1. Nirmatrelvir/ritonavir (Paxlovid) - first choice for most high-risk patients
  2. Remdesivir (IV, 3-day course) - used if Paxlovid is contraindicated due to drug-drug interactions
  3. Molnupiravir - when the above are not feasible (FDA EUA for adults)

Hospitalized / Severe illness

  • Remdesivir (200 mg IV day 1, then 100 mg daily) - speeds recovery, especially if given within 10 days of symptom onset before mechanical ventilation
  • Dexamethasone - mainstay anti-inflammatory for patients requiring oxygen
  • IL-6 inhibitors (e.g., tocilizumab) or JAK inhibitors (e.g., baricitinib) - for select patients
  • Therapeutic anticoagulation - for some patients with severe disease (thrombotic risk)
  • Careful oxygenation management and organ support in the ICU
Not recommended: Ivermectin (no proven benefit), prophylactic aspirin/anticoagulation in outpatients without other indications. - Goldman-Cecil Medicine, p. 3551

Extrapulmonary Complications

COVID-19 can affect nearly every organ:
  • Cardiac: myocarditis, myocardial infarction, arrhythmias, thrombosis
  • Neurologic: delirium, encephalitis, seizures, myoclonus
  • Renal: AKI (about 1/3 of ventilated patients need dialysis)
  • Skin: maculopapular eruptions, urticaria, vesicles
  • Of hospitalized patients: ~15% need ICU, ~12% need mechanical ventilation, ~3-4% need dialysis. - Goldman-Cecil Medicine, p. 3547

Long COVID

Symptoms persisting at least 1 month after acute infection and lasting 2+ months = long COVID (also called PASC - post-acute sequelae of SARS-CoV-2). Estimated prevalence: ~6% of people who had COVID-19. Common features:
  • Physical: fatigue, weakness, dyspnea, chest pain, cough
  • Cognitive/psychological: "brain fog," memory/concentration problems, anxiety, depression, PTSD
Risk factors: female sex, severe acute illness, age >20, unvaccinated status. Most recover within a year. - Robbins Pathology, p. 331

When to Seek Medical Care

  • Symptoms worsen after several days
  • Persistent high fever (>3 days)
  • Chest pain or breathing difficulty
  • Any high-risk group (elderly, immunocompromised, pregnant, chronic illness)
For current treatment guidelines, see the NIH COVID-19 Treatment Guidelines and IDSA COVID-19 guidelines.
Recent evidence: A 2024 systematic review and meta-analysis (PMID: 39288386) confirmed that Paxlovid (nirmatrelvir/ritonavir) significantly reduces hospitalization and death in high-risk patients with mild-to-moderate COVID-19, supporting its continued use as first-line outpatient antiviral therapy.
This is a shared conversation. Sign in to Orris to start your own chat.